Description: Appili Therapeutics Inc., a biopharmaceutical company, acquires, develops, and commercializes novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1501, a taste-masked oral liquid suspension formulation of an antibiotic, metronidazole; ATI-1503 that develops a class of gram-negative targeting antibiotics; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was founded in 2015 and is headquartered in Halifax, Canada.
Home Page: www.appilitherapeutics.com
#21-1344 Summer Street
Halifax,
NS
B3H 0A8
Canada
Phone:
902 442 4655
Officers
| Name | Title |
|---|---|
| Dr. Donald D. Cilla Jr., M.B.A., Pharm.D., Pharmd | CEO, Pres & Director |
| Mr. Kenneth G. Howling | Acting Chief Financial Officer |
| Dr. Yoav Golan M.S., M.D., MS | Chief Medical Officer |
Exchange: OTCQX
Country: US
Currency: US Dollar ($)
| Forward PE: | 1.7068 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4792 |
| Price-to-Sales TTM: | 3.9772 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 8 |